Escalating breast cancer incidence rate is the prime reason behind the demand for various types of Breast Cancer Therapeutics worldwide, especially in developed regions such as the United States and Europe. In the U.S., as per Breast Cancer Org, 276,480 new cases of invasive breast cancer and 48,530 new cases of non-invasive breast cancer are estimated to be diagnosed in 2020. Globally, more than 1.7 million new cases of breast cancer are diagnosed every year; out of which a significant proportion is in developed nations. Increasing technological advances in cancer biology and the launch of several diagnostic and screening programs worldwide should drive the business size.